What is the appropriate evaluation and management for a patient with a history of recurrent melanoma, including a lower eyelid melanoma excised seven years ago?

Management of Recurrent Melanoma with History of Lower Eyelid Involvement

For a patient with recurrent melanoma and a history of lower eyelid melanoma excised seven years ago, you must initiate comprehensive surveillance imaging, perform complete excision of any new lesions with histopathologic confirmation, and strongly consider adjuvant systemic therapy (immunotherapy or targeted therapy based on BRAF status) if the recurrence represents stage III disease after complete resection.

Immediate Evaluation Steps

Clinical Assessment

• Examine all previous melanoma sites for local recurrence, including the lower eyelid region and surrounding periocular skin
• Palpate regional lymph nodes (preauricular, cervical, submandibular) for nodal metastases
• Document any new pigmented lesions, subcutaneous nodules, or in-transit metastases anywhere on the body

Diagnostic Workup

The NCCN guidelines 1 recommend staging based on clinical presentation:

• Biopsy any suspicious lesions with complete/excisional technique (1-3 mm margins) to establish definitive diagnosis and allow proper microstaging
• Obtain Breslow depth, ulceration status, and mitotic rate from pathology—these determine staging and guide sentinel lymph node biopsy (SLNB) decisions
• Consider ultra-high-frequency ultrasound (UHFUS) for periocular surveillance, as this can detect clinically subtle recurrent nodules in previously treated areas 2
• Imaging for metastatic workup if clinically indicated based on symptoms or examination findings

Critical Pitfall: Late Recurrences Are Real

Eyelid and conjunctival melanomas have exceptionally high recurrence rates—one study showed 54% local recurrence at mean 43 months, with some recurrences occurring up to 21-25 years after initial treatment 3, 4. The seven-year interval in this patient falls well within the documented recurrence window. Do not assume the patient is "cured" based on time elapsed.

Surgical Management

For Confirmed Recurrence

• Wide excision (WE) is the gold standard for any confirmed melanoma recurrence 1
• SLNB should be performed at time of WE if clinically node-negative and tumor characteristics warrant staging (Breslow depth, ulceration, mitotic rate)
• Globe-sparing approaches may be considered for selected periocular cases, though this requires accepting higher local recurrence risk while preserving vision 3, 5

Extent of Surgery

The research evidence shows that even aggressive surgery (including exenteration) does not eliminate recurrence or metastatic risk in eyelid melanoma—all melanoma-related deaths in one cohort occurred in patients who underwent exenteration 3. This suggests:

• Prioritize complete excision with clear margins over increasingly radical procedures
• Balance oncologic control with quality of life, particularly vision preservation when feasible

Adjuvant Systemic Therapy

If the recurrence represents completely resected stage III disease (regional nodal involvement, in-transit metastases, or microsatellites), adjuvant therapy is indicated 1, 6.

Treatment Options

• Immunotherapy (anti-PD-1 agents like pembrolizumab or nivolumab)
• Targeted therapy (BRAF/MEK inhibitors if BRAF V600 mutation positive)

Key Considerations

• Test for BRAF mutation status on the recurrent tumor—this may differ from the original lesion or provide new information if not previously tested 4
• Adjuvant therapy improves disease-free survival in resected stage III melanoma 1
• The ESMO guidelines note that patients with completely resected in-transit melanoma or microsatellites should be considered for adjuvant therapy even without nodal involvement 6

Special Consideration: If Recurrence Occurs During Adjuvant Therapy

This scenario indicates potential resistance to the current regimen 6. The decision to continue, switch, or stop therapy must account for:

• BRAF mutation status (allows switching between immunotherapy and targeted therapy)
• Pattern of recurrence (isolated locoregional vs. multiple sites)
• Tolerance to current therapy
• Patient preferences and performance status

The ESMO consensus acknowledges this remains controversial with Level IV evidence 6, but resistance should be assumed in most cases.

Long-Term Surveillance Protocol

Given the documented risk of very late recurrences (up to 25 years) 4:

• Lifelong surveillance is mandatory, not just 5-year follow-up
• Patient education about self-examination and prompt reporting of new lesions
• Regular dermatologic and ophthalmologic examination of the periocular region
• Consider UHFUS for periocular surveillance in high-risk cases 2
• Maintain awareness that recurrence can occur even after exenteration through dormant tumor cells or residual intraepithelial melanocytes 4

Pathology Pearls

Periocular melanomas can be diagnostically challenging—ensure pathology includes:

• S100 and SOX10 immunostaining (positive in both melanoma and neural tumors)
• Melanocytic markers (HMB-45, Melan-A, MART-1)
• Request molecular testing if diagnosis is ambiguous, as desmoplastic melanoma can mimic neurofibroma 7
• Breslow depth, ulceration, mitotic rate, and lymphovascular invasion for staging 1